Blood glucose changes surrounding initiation of tumor-necrosis factor inhibitors and conventional disease-modifying anti-rheumatic drugs in veterans with rheumatoid arthritis

Wood, Patrick; Manning, Evan; Baker, Joshua F.; England, Bryant R.; Davis, Lisa; Cannon, Grant W.; Mikuls, Ted R.; Caplan, Liron

doi:10.4239/wjd.v9.i2.53

Cited by 6 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tumour necrosis factor has been implicated in the development of IR and T2D, despite conflicting results of antagonising this cytokine in patients with this metabolic disease [110,111]. In the context of RA, several studies analysed the effects of TNFis (i.e., adalimumab, etanercept, and infliximab) on glucose metabolism, mostly assessing IR and IS by Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) and Quantitative Insulin sensitivity ChecK Index (QUICKI), respectively [112][113][114][115][116][117].…”

Section: Tnf Inhibitorsmentioning

confidence: 99%

Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association

2022

View full text Add to dashboard Cite

Multiple lines of evidence have increasingly suggested a pathogenic connection between rheumatoid arthritis (RA) and the mechanisms of type 2 diabetes (T2D) in a vicious circle perpetuated by glucose derangement and inflammatory mediators. These findings have been further reinforced by clinical studies showing that the inhibition of interleukin (IL)-1 and IL-6 may allow the treatment of RA and concomitant T2D at the same time. Interestingly, IL-1 inhibition induced a more evident reduction of glycated haemoglobin (HbA1c) in patients with concomitant RA and T2D than in previous studies on IL-1 inhibition in patients with this metabolic disease alone. Thus, the inflammatory pathogenic mechanisms of T2D could be exaggerated in the context of a rheumatic disease, possibly explaining these findings. In fact, IL-1 inhibition could not only palliate glycaemia, but also decrease the progressive decline in insulin secretion associated with T2D, interfering with apoptosis of β-cells, improving their function, and ameliorating the peripheral insulin resistance. Moreover, the maintenance of clinical remission of rheumatic disease could further improve the glucose derangement and reduce the occurrence of T2D in RA. On these bases, the presence of T2D may allow the physicians to perform a better profile of patients with RA according to the principles of precision medicine, tailoring the medical treatment to the individual characteristics. In this context, the benefits of targeting the inflammatory process, mainly by IL-1 inhibition, may be suggested in patients with RA and concomitant T2D.

show abstract

Section: Tnf Inhibitorsmentioning

confidence: 99%

Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association

2022

View full text Add to dashboard Cite

show abstract

“…In a cohort of 522 non-diabetic RA cases receiving the TNF-α inhibitors (TNFis) including ADA, ETA, GLO and IFX, there was a more than 50% reduction in the risk of DM development[ 61 ]. Nevertheless, another retrospective observational study with 2111 RA patients, not excluding DM, failed to demonstrate hypoglycemic effects at 6 mo following the initiation of TNFi therapy with ETA and four other mAbs[ 62 ]. Since hyperglycemia, a critical contributor to IR, can interfere with the effects of TNFi on insulin sensitivity, most published reports examined the studied population in non-diabetic RA patients.…”

Section: Role Of Tnf-α In Irmentioning

confidence: 99%

Anti- and non-tumor necrosis factor-α-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Wang¹,

Tsai²

2021

WJD

View full text Add to dashboard Cite

In addition to β-cell failure with inadequate insulin secretion, the crucial mechanism leading to establishment of diabetes mellitus (DM) is the resistance of target cells to insulin, i.e . insulin resistance (IR), indicating a requirement of beyond-normal insulin concentrations to maintain euglycemic status and an ineffective strength of transduction signaling from the receptor, downstream to the substrates of insulin action. IR is a common feature of most metabolic disorders, particularly type II DM as well as some cases of type I DM. A variety of human inﬂammatory disorders with increased levels of proinflammatory cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-1β, have been reported to be associated with an increased risk of IR. Autoimmune-mediated arthritis conditions, including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with the involvement of proinflammatory cytokines as their central pathogenesis, have been demonstrated to be associated with IR, especially during the active disease state. There is an increasing trend towards using biologic agents and small molecule-targeted drugs to treat such disorders. In this review, we focus on the effects of anti-TNF-α- and non-TNF-α-targeted therapies on IR in patients with RA, PsA and AS. Anti-TNF-α therapy, IL-1 blockade, IL-6 antagonist, Janus kinase inhibitor and phospho-diesterase type 4 blocker can reduce IR and improve diabetic hyper-glycemia in autoimmune-mediated arthritis.

show abstract

“…К сожалению, авторы не приводят сведений о сопутствующей терапии, в том числе о сахароснижающих препаратах, что вызывает сомнения в правомочности подобного вывода. В других исследованиях иФНОα [ИНФ, ЭТЦ, АДА, цертолизумаба пэгол (ЦЗП), ГЛМ] при РА, анкилозирующем спондилите (АС), ПсА и ювенильном идиопатическом артрите не оказывали подобного гипогликемического эффекта, уровень HbA1c оставался стабильным [6,7]. У пациентов с ожирением и СД 2-го типа краткосрочное (до 4 нед) применение иФНОα не влияло на инсулинорезистентность (ИР) [8][9][10].…”

Section: ингибиторы фак тора некроза опухоли α αunclassified

Influence of biologics on carbohydrate metabolism and risk of diabetes

Кондратьева¹,

Попкова²,

Насонов

2019

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

Blood glucose changes surrounding initiation of tumor-necrosis factor inhibitors and conventional disease-modifying anti-rheumatic drugs in veterans with rheumatoid arthritis

Cited by 6 publications

References 16 publications

Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association

Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association

Anti- and non-tumor necrosis factor-α-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Influence of biologics on carbohydrate metabolism and risk of diabetes

Contact Info

Product

Resources

About